Guerbet : H1 2026 Results.

Guerbet reported H1 2026 revenue of €379.2m, down 2.2% reported and broadly flat (-0.1%) on a constant-currency, like-for-like basis, while EBITDA fell to €30.6m from €46.1m and net loss widened to €32.7m from a €1.3m profit. The restated EBITDA margin contracted 380bps year over year to 9.1%, with €14.3m of exceptional Raleigh remediation costs; free cash flow was -€30.2m and net debt rose to €355.9m, resulting in 5.3x leverage. The company has covenant waivers but must finalize a refinancing arrangement by October 31, 2026, while maintaining full-year guidance for approximately 8% restated EBITDA margin and materially negative FCF of €50m-€70m.

Analysis

GBT is now principally a capital-structure trade rather than an operating recovery story. The combination of continuing cash burn, elevated leverage and a near-term refinancing negotiation gives lenders effective control over equity value; even a successful amendment likely carries higher interest expense, tighter covenants and potentially equity-like dilution. The CFO transition during negotiations raises execution risk and should widen the discount investors require until terms are disclosed.

The key 1-3 month catalyst is the refinancing outcome, not the October revenue print. A clean maturity extension without an equity raise could produce a sharp relief rally from distressed valuation levels, but the asymmetry remains negative: failure to finalize by the stated deadline, a rights issue, or pricing materially above existing debt costs would reset the equity lower. The relevant verification points are liquidity headroom after restructuring cash costs, lender covenant package, and whether the U.S. remediation converts into sustainably normal production rather than merely improved release rates.

Over 6-18 months, the turnaround requires simultaneous normalization in U.S. manufacturing, Chinese commercial-model conversion and cost savings—three initiatives that can each disrupt margin or working capital. A more subtle risk is that direct selling in China improves channel control but initially shifts inventory, receivables and salesforce cost onto GBT, worsening cash conversion precisely when financing flexibility is constrained. Faster-growing interventional radiology offers strategic value, but it is unlikely to offset balance-sheet pressure absent demonstrable group-level margin recovery.

Contrarian case: the market may over-penalize GBT if lenders prioritize preserving a specialized medical-imaging franchise and remediation ends on schedule; waiver history suggests banks have incentive to avoid a destructive process. That thesis is falsified by another regulatory delay, weaker U.S. sales despite normalized operations, or refinancing requiring material new equity/coupon burden. There is no read-through to BNP, ENX or broad French equities without disclosure of specific creditor exposures.

Key Decisions for Investors

• Maintain/establish a tactical short or underweight in GBT into the refinancing deadline; size modestly because a consensual extension can trigger a violent relief rally. Cover on disclosed non-dilutive refinancing with maturities pushed beyond 2028 and credible liquidity headroom, rather than on management assurances.
• For existing GBT holders, do not average down before financing terms. Treat a rights issue, convertibles, security package, or all-in debt cost as the decision point; these determine residual equity value more than the next quarterly sales print.
• Set an event-driven alert for the Q3 release and any financing announcement: upgrade only if U.S. recovery is accompanied by evidence of lower remediation cash outflow and stable working capital, not simply revenue growth.
• Avoid using BNP as a hedge or sympathy trade absent confirmation of a lending exposure; the issuer-specific refinancing is too small and opaque to support a bank-sector position.